uniQure (QURE): The FDA Story Is Two Months Old. The Q3 BLA Is The Question.

The FDA alignment headline is recycled news. On June 17, the FDA agreed that three-year Phase I/II data... would be sufficient to support a Biologics License Application for accelerated approval in Huntington's disease. The stock surged 80% that day, jumping to roughly $48. The 6.4% move investors are chasing today is the five-day drift through August, not a fresh catalyst.

The actual story now is different. UniQure promised the BLA would land in Q3 2026 — the July-through-September window. We're two-thirds of the way through September and there's no filing. The company still needs to reach agreement with the FDA on the confirmatory study design that comes with accelerated approval, including whether a sham-surgery control group will be required. That's the gap between a press release and a drug on the market.

Here's what the math says.

1. The FDA pendulum swung, then paused.

The regulatory ride has been a three-act play. In December 2024, the FDA first agreed to an accelerated approval pathway. In November 2025, it reversed course, rejecting the external control methodology and demanding a sham-surgery-controlled trial. By March 2026, the agency had formally ruled that Phase I/II data were insufficient for a marketing application. Then, following leadership changes at the FDA — Vinay Prasad's departure in April 2026, Commissioner Marty Makary's resignation in mid-May — the agency reversed again in June, accepting the three-year Phase I/II dataset.

The pattern is clear: regulatory outcomes shifted with personnel, not clinical data. The AMT-130 trial results haven't changed. What changed was who was reviewing them. Analysts at Guggenheim and RBC Capital Markets attributed the reversal to a more flexible "caretaker" FDA. That's plausible. It's also a reminder that regulatory tailwinds can change direction when leadership changes direction.

2. The BLA timeline is the new risk.

UniQure committed to a Q3 2026 filing. A BLA is not a formality — it's a massive regulatory document, and the FDA explicitly requested alignment on the confirmatory study design before the marketing application is submitted. Accelerated approval typically requires the confirmatory trial to already be underway, sometimes with full enrollment, at the time of approval. The company hasn't said whether it's building that trial in parallel or waiting for the BLA decision.

The delay between the June announcement and the present suggests the confirmatory study design is the sticking point. If Q3 passes without a filing, the market's $3.22B vote of confidence will start looking like it assumed too much.

3. The economics don't support a $3.22B market cap without a filed BLA.

QURE trades at a $3.22B market cap with $413M in cash, $661M in total debt, and a trailing twelve-month free cash flow burn of $161.5M. That's roughly $40M per quarter. The cash runway is about 10 quarters at that pace, which is comfortable but not infinite. The company has no commercial revenue. No product on the market. No approved indication.

The enterprise value — market cap minus net cash — is $2.46B. That's what the business itself is worth. The stock is up 254% over the trailing 12 months and 94% year-to-date, climbing from a 52-week low of $8.73. It's down only 4% from the June 17 intraday peak of roughly $48.51, which means the market hasn't given back the FDA reversal trade despite a two-month silence on filing progress.

For context, the market is implicitly assigning AMT-130 a high probability of near-term approval and a lucrative commercial ramp in Huntington's disease, where roughly 75,000 patients are affected across the U.S., Europe, and the U.K. and no current treatments slow progression. The commercial case is real. The question is whether $2.46B of enterprise value is justified before the application is even in the regulator's hands.

4. The external control methodology is still the structural risk.

AMT-130's efficacy evidence comes from comparing treated patients against a propensity score-matched external control group drawn from the Enroll-HD natural history database, rather than a concurrent randomized control arm. The FDA accepted this approach in June, but external controls remain subject to significant regulatory scrutiny in neurodegenerative indications, where disease progression can be noisy and heterogeneous. The confirmatory study the FDA is insisting on — potentially with a sham-surgery control — is the agency's way of hedging against that weakness.

This isn't a drug failure. The Phase I/II data showed a 75% slowing of disease progression in the UK dataset, which is meaningful for a condition where patients face progressive motor dysfunction, cognitive decline, and psychiatric symptoms. But accelerated approval is a conditional pass, not a permanent one. If the confirmatory trial underperforms, the approval can be withdrawn.

The setup.

This is a binary event stock, not a compounder. AMT-130 is a one-time gene therapy delivered via stereotactic neurosurgery into the striatum to reduce mutant huntingtin protein production. If it gets approved, the Huntington's market is small but desperate, with no disease-modifying options and regulatory designations (RMAT, Breakthrough Therapy, Fast Track) already in place. If it doesn't, the $3.22B market cap collapses.

The BLA filing in Q3 is the catalyst that matters right now. A filing before September ends would confirm the company is on track and the FDA's current flexibility holds. A miss would signal that the confirmatory study negotiations are harder than the June press release suggested.

QURE sits at $46, down only 4% from the post-announcement peak. The stock has already priced in a high-probability approval scenario. That means the gap between "FDA said yes in principle" and "drug is approved and on the market" — which typically takes months to years, including confirmatory trial execution — is the compression that hasn't been tested yet.

The break condition is simple: a BLA filing. If uniQure files before Q3 closes, the thesis that the FDA path is open gets confirmed. If it slips into Q4, the question becomes whether the market's $3.22B bid can hold through regulatory uncertainty. Either way, the FDA alignment story is old news. The filing is what's left.

At roughly $46, the stock is up 254% over the past year. The forward math works only if the BLA files on schedule, the accelerated approval follows, and the confirmatory trial doesn't derail the deal. Three moving parts, all unproven. The stock may have already run ahead of the evidence.